|
Harold C. Standiford, MD, FACP
Professor of Medicine
Director, Infection Control and Antimicrobial Effectiveness
MD: University of Maryland School of Medicine, 1964
Phone: (410) 328-5757
Fax: (410) 328-0089
E-mail: hstandiford@umm.edu
Address:
Division of Infectious Diseases
Infection Control & Antimicrobial Effectiveness
Suite 400, 29 South Greene Street
Baltimore, MD 21201
RESEARCH INTERESTS
Dr. Standiford is the Medical Director for Infection Control and Antimicrobial Effectiveness. He has extensive experience in clinical research and has publications relating to control of methicillin resistant staphylococcus aureus, HIV, and endocarditis. His clinical trial experience includes those in phases I-III in development, using antimicrobial agents singly or in combination, and involving single sites or cooperative ventures.
SELECTED PUBLICATIONS
- Standiford HC, DeMaine JB, Kirby WM: Antibiotic synergism of enterococci, relation to inhibitory concentrations. Arch Intern Med 126:255-259, 1970.
- Walsh TJ, Vlahov D, Hansen SL, Sonnenberg E, Khabbaz R, Gadacz T, Standiford HC: Prospective microbiologic surveillance in control of methicillin-resistant Staphylococcus aureus. Infection Control 8:7-14, 1987.
- Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, Montgomerie JZ, Goetz MB, Mayhall CG, Rimland D, Stevens DA, Hansen SL, Gerard GC, Ragual RJ. Randomized Double-Blinded Trial of Rifampin with Either Novobiocin or Trimethoprim-Sulfamethoxazole against Methicillin Resistant Staphylococcus aureus Colonization: Prevention of Antimicrobial Resistance and the Effect of Host Factors on Outcome. Antimicrob Agents and Chemotherapy. 37:1334-1342, 1993.
- Hafner R, Inderlied CB, Peterson DM, Wright DJ, Standiford HC, Drusano G, Muth K, and the Division of AIDS Treatment Research Initiative Protocol 007 Study Group. Correlation of Quantitative Bone Marrow and Blood Cultures in AIDS Patients with Disseminated Mycobacterium Avium Complex Infection. JID 180:438-47, 1999.
- Wong MT, Kauffman CA, Standiford HC, Linden P, Fort G, Fuchs HJ, Porter SB, Wenzel RP and the Ramoplanin VRE Clinical Study Group. Effective suppression of vancomycin- resistant enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001: 33:1476-1482.
 Back to Primary Faculty
To contact us:
Phone: 410-706-7560
Fax: 410-706-4619
E-mail: kvardjan@ihv.umaryland.edu
 Back to Top of Page
|
